We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
Read MoreHide Full Article
Veracyte, Inc. (VCYT - Free Report) delivered first-quarter 2025 earnings of 31 cents per share, which marked a stupendous improvement of 63.2% from the year-ago period’s figure of 19 cents. The bottom line beat the Zacks Consensus Estimate by 55%.
The company-adjusted earnings per share (EPS) were 9 cents compared to the year-ago period’s loss of 2 cents per share.
Following the earnings announcement, VCYT’s share price gained 1.2% yesterday.
VCYT’s Q1 Revenues
Revenues increased 18.3% year over year to $114.5 million, which outpaced the Zacks Consensus Estimate by 3.2%. (See the Zacks Earnings Calendar to stay ahead of market-making news.)
VCYT’s Q1 Segmental Details
Testing revenues totaled $107.3 million, up 19% year over year. This rise was mainly due to Decipher and Afirma revenue growth of 33% and 6%, respectively. Testing volume improved 23% year over year to 38,078 tests.
Product revenues rose 1% year over year to $3.6 million in the first quarter. Volume was approximately 2,570 tests, up 1% year over year.
Biopharmaceutical and other revenues of $3.6 million reflected a 19% increase from the prior-year quarter’s figure.
Margins
The total cost of revenues (product, testing, biopharmaceutical and other) was $35 million, up 1.7% year over year.
The gross profit rose 27.3% to $79.5 million. The gross margin expanded 495 basis points (bps) to 69.5%.
Selling and marketing expenses rose 2.8% to $24.4 million, while general and administrative expenses increased 29% to $33.8 million. R&D expenses totaled $17.7 million, up 11% year over year. The company delivered an operating profit of $3.5 million compared to a loss of $3.5 million in the year-ago period.
VCYT’s Cash, Capital Structure and Solvency
Veracyte exited first-quarter 2025 with cash and cash equivalents of $186.1 million compared with $239.1 million at the end of the fourth quarter of 2024.
The net cash provided from operating activities at the end of the reported quarter was $5.4 million against $9 million net cash used in operating activities a year ago.
Guidance
Veracyte reaffirmed its full-year 2025 testing revenue guidance. The company expects testing revenues to be in the range of $470-$480 million, implying 12-15% year-over-year growth.
Henry Schein, Inc. Price, Consensus and EPS Surprise
The company raised guidance for adjusted EBITDA as a percentage of revenues. It is anticipated to be approximately 22.5% (up from the previous guidance of 21.6%).
Our Take
Veracyte reported better-than-expected first-quarter results, with its earnings and revenues surpassing their respective estimates. The company registered robust growth from its market-leading Decipher Prostate and Afirma tests. Meanwhile, the growth in Product revenues and Biopharmaceutical and other revenues was encouraging. The gross margin expansion instills optimism among investors.
In the first quarter, the company had some notable developments, including the launch of Decipher for metastatic prostate cancer patients. It also published analytical validity data for the Percepta Nasal Swab.
Zacks Rank and Other Key Picks
Veracyte currently carries a Zacks Rank #2 (Buy).
Other top-ranked stocks from the broader medical space are AngioDynamics (ANGO - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Boston Scientific (BSX - Free Report) .
AngioDynamics, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a loss of 13 cents. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 composite’s 10.5%. The company surpassed earnings estimates in each of the trailing four quarters, the average surprise being 70.9%.
Integer Holdings, sporting a Zacks Rank #1 at present, posted a first-quarter 2025 adjusted EPS of $1.31, which outpaced the Zacks Consensus Estimate by 3.1%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%.
ITGR has an estimated long-term earnings growth rate of 20.8% compared with the industry’s 14.3%. The company’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 2.8%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a first-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 2.3%.
BSX has an estimated 2025 earnings growth rate of 15.9% compared with the S&P 500 composite’s 11.9%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
Veracyte, Inc. (VCYT - Free Report) delivered first-quarter 2025 earnings of 31 cents per share, which marked a stupendous improvement of 63.2% from the year-ago period’s figure of 19 cents. The bottom line beat the Zacks Consensus Estimate by 55%.
The company-adjusted earnings per share (EPS) were 9 cents compared to the year-ago period’s loss of 2 cents per share.
Following the earnings announcement, VCYT’s share price gained 1.2% yesterday.
VCYT’s Q1 Revenues
Revenues increased 18.3% year over year to $114.5 million, which outpaced the Zacks Consensus Estimate by 3.2%. (See the Zacks Earnings Calendar to stay ahead of market-making news.)
VCYT’s Q1 Segmental Details
Testing revenues totaled $107.3 million, up 19% year over year. This rise was mainly due to Decipher and Afirma revenue growth of 33% and 6%, respectively. Testing volume improved 23% year over year to 38,078 tests.
Product revenues rose 1% year over year to $3.6 million in the first quarter. Volume was approximately 2,570 tests, up 1% year over year.
Biopharmaceutical and other revenues of $3.6 million reflected a 19% increase from the prior-year quarter’s figure.
Margins
The total cost of revenues (product, testing, biopharmaceutical and other) was $35 million, up 1.7% year over year.
The gross profit rose 27.3% to $79.5 million. The gross margin expanded 495 basis points (bps) to 69.5%.
Selling and marketing expenses rose 2.8% to $24.4 million, while general and administrative expenses increased 29% to $33.8 million. R&D expenses totaled $17.7 million, up 11% year over year. The company delivered an operating profit of $3.5 million compared to a loss of $3.5 million in the year-ago period.
VCYT’s Cash, Capital Structure and Solvency
Veracyte exited first-quarter 2025 with cash and cash equivalents of $186.1 million compared with $239.1 million at the end of the fourth quarter of 2024.
The net cash provided from operating activities at the end of the reported quarter was $5.4 million against $9 million net cash used in operating activities a year ago.
Guidance
Veracyte reaffirmed its full-year 2025 testing revenue guidance. The company expects testing revenues to be in the range of $470-$480 million, implying 12-15% year-over-year growth.
Henry Schein, Inc. Price, Consensus and EPS Surprise
Henry Schein, Inc. price-consensus-eps-surprise-chart | Henry Schein, Inc. Quote
The company raised guidance for adjusted EBITDA as a percentage of revenues. It is anticipated to be approximately 22.5% (up from the previous guidance of 21.6%).
Our Take
Veracyte reported better-than-expected first-quarter results, with its earnings and revenues surpassing their respective estimates. The company registered robust growth from its market-leading Decipher Prostate and Afirma tests. Meanwhile, the growth in Product revenues and Biopharmaceutical and other revenues was encouraging. The gross margin expansion instills optimism among investors.
In the first quarter, the company had some notable developments, including the launch of Decipher for metastatic prostate cancer patients. It also published analytical validity data for the Percepta Nasal Swab.
Zacks Rank and Other Key Picks
Veracyte currently carries a Zacks Rank #2 (Buy).
Other top-ranked stocks from the broader medical space are AngioDynamics (ANGO - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Boston Scientific (BSX - Free Report) .
AngioDynamics, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a loss of 13 cents. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 composite’s 10.5%. The company surpassed earnings estimates in each of the trailing four quarters, the average surprise being 70.9%.
Integer Holdings, sporting a Zacks Rank #1 at present, posted a first-quarter 2025 adjusted EPS of $1.31, which outpaced the Zacks Consensus Estimate by 3.1%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%.
ITGR has an estimated long-term earnings growth rate of 20.8% compared with the industry’s 14.3%. The company’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 2.8%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a first-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 2.3%.
BSX has an estimated 2025 earnings growth rate of 15.9% compared with the S&P 500 composite’s 11.9%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%.